Moving to tolerance: Clinical application of T regulatory cells

被引：74

作者：

McMurchy, Alicia N. ^{[1
,2
]}

Bushell, Andrew ^{[3
]}

Levings, Megan K. ^{[1
,2
]}

Wood, Kathryn J. ^{[3
]}

机构：

[1] Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada

[2] Univ British Columbia, Dept Surg, Vancouver, BC V5Z 1M9, Canada

[3] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg Sci, Oxford OX3 9DU, England

来源：

SEMINARS IN IMMUNOLOGY | 2011年 / 23卷 / 04期

基金：

英国惠康基金; 英国医学研究理事会;

关键词：

Transplantation; T regulatory cells; Cellular therapy; Drug minimization; Translational medicine; CARDIAC ALLOGRAFT SURVIVAL; VERSUS-HOST-DISEASE; RENAL-TRANSPLANT TOLERANCE; LATENT TGF-BETA; EX-VIVO; IN-VITRO; FOXP3; EXPRESSION; CUTTING EDGE; SUICIDE-GENE; TREG CELLS;

D O I：

10.1016/j.smim.2011.04.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Decreasing the incidence of chronic rejection and reducing the need for life-long immunosuppression remain important goals in clinical transplantation. In this article, we will review how regulatory T cells (Treg) came to be recognized as an attractive way to prevent or treat allograft rejection, the ways in which Treg can be manipulated or expanded in vivo, and the potential of in vitro expanded/generated Treg for cellular therapy. We will describe the first regulatory T cell therapies that have been or are in the process of being conducted in the clinic as well as the safety concerns of such therapies and how outcomes may be measured. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：304 / 313

页数：10

共 142 条

[1] Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease [J].

Adkins, Douglas ;

Ratanatharathorn, Voravit ;

Yang, Harry ;

White, Barbara .

TRANSPLANTATION, 2009, 88 (02) :198-202

[2] Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3 [J].

Allan, Sarah E. ;

Alstad, Alicia N. ;

Merindol, Natacha ;

Crellin, Natasha K. ;

Amendola, Mario ;

Bacchetta, Rosa ;

Naldini, Luigi ;

Roncarolo, Maria Grazia ;

Soudeyns, Hugo ;

Levings, Megan K. .

MOLECULAR THERAPY, 2008, 16 (01) :194-202

[3] Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production [J].

Allan, Sarah E. ;

Crome, Sarah Q. ;

Crellin, Natasha K. ;

Passerini, Laura ;

Steiner, Theodore S. ;

Bacchetta, Rosa ;

Roncarolo, Maria G. ;

Levings, Megan K. .

INTERNATIONAL IMMUNOLOGY, 2007, 19 (04) :345-354

[4] Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3 [J].

Allan, Sarah E. ;

Song-Zhao, George X. ;

Abraham, Thomas ;

McMurchy, Alicia N. ;

Levings, Megan K. .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (12) :3282-3289

[5] CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-β-dependent manner [J].

Andersson, John ;

Tran, Dat Q. ;

Pesu, Marko ;

Davidson, Todd S. ;

Ramsey, Heather ;

O'Shea, John J. ;

Shevach, Ethan M. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (09) :1975-1981

[6]

ANDREOLA G, AM J TRANSP IN PRESS

[7] Defective regulatory and effector T cell functions in patients with FOXP3 mutations [J].

Bacchetta, Rosa ;

Passerini, Laura ;

Gambineri, Eleonora ;

Dai, Minyue ;

Allan, Sarah E. ;

Perroni, Lucia ;

Dagna-Bricarelli, Franca ;

Sartirana, Claudia ;

Matthes-Martins, Susanne ;

Lawitschka, Anita ;

Azzari, Chiara ;

Ziegler, Steven F. ;

Levings, Megan K. ;

Roncarolo, Maria Grazia .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (06) :1713-1722

[8] Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy [J].

Bacchetta, Rosa ;

Gregori, Silvia ;

Serafini, Giorgia ;

Sartirana, Claudia ;

Schulz, Ute ;

Zino, Elisabetta ;

Tomiuk, Stefan ;

Jansen, Uwe ;

Ponzoni, Maurilio ;

Paties, Carlo Terenzio ;

Fleischhauer, Katharina ;

Roncarolo, Maria Grazia .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (12) :2134-2143

[9] Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin [J].

Basu, Samik ;

Golovina, Tatiana ;

Mikheeva, Tatiana ;

June, Carl H. ;

Riley, James L. .

JOURNAL OF IMMUNOLOGY, 2008, 180 (09) :5794-5798

[10] Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells [J].

Battaglia, M ;

Stabilini, A ;

Roncarolo, MG .

BLOOD, 2005, 105 (12) :4743-4748

← 1 2 3 4 5 6 7 8 9 10 →